search
Back to results

Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases

Primary Purpose

Neoplasm Metastasis, Spinal Cord Diseases, Spinal Cord Compression

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Stereotactic Laser Ablation
Stereotactic Radiosurgery
MRI guided laser ablation
Sponsored by
Henry Ford Health System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neoplasm Metastasis focused on measuring Laser Ablation, Spinal Cord, Minimally Invasive Surgical Procedure, Stereotactic Radiosurgery, Pain Control, Metastasis, Epidural Tumor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18 years old. (The indication for this technique is controversial in skeletally immature patients.)
  • Histologic diagnosis of solid malignant tumor (not one of the more radiosensitive histologic subtypes, see Exclusion Criteria), including but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and unknown primary tumors.
  • Quantification of the degree of epidural spinal cord compression as grade 1C, 2, or 3 by MRI, with and without contrast sequences. Axial T2 sequence is encouraged but not required.
  • The vertebral body site to be treated must be located from T2 to L1
  • No more than 3 contiguous or dis-contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session or 3 sessions.
  • Motor strength ≥4 out of 5 in extremity or extremities affected by the level of the spinal cord compression (see section 4 for grading method).
  • ECOG performance status <2 or Karnofsky performance status (KPS) >50
  • Life expectancy >3 months.
  • Inoperable disease because of patient refusal, neurosurgical evaluation, or any other medical reasons.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Prior conventional radiation to the same site is allowed as long as there is a greater than 3 months interval.
  • Signed informed consent.

Exclusion Criteria:

  • Requires open spinal procedure or a percutaneous procedure without the use of image guidance.
  • Primary tumors of radiosensitive histology (lymphoma, multiple myeloma, small cell carcinoma, germ cell tumors), as conventional radiation is likely to be effective in such cases.
  • Unable to tolerate general anesthesia and prone position.
  • Unable to undergo MRI scan of the spine.
  • Inability to lie flat on a treatment table for >60 minutes.
  • Pregnant. (Urine testing must be done no more than 10 days prior to surgery.)
  • Prior conventional irradiation of the spine site and level to be treated with an interval shorter than 3 months.
  • Frank cord compression or cord compression from bone components or configuration and acute neurological deficits (defined as motor strength <4/5 in extremity or extremities affected by the level of the spinal cord compression)

Sites / Locations

  • Henry Ford HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery

Arm Description

Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.

Outcomes

Primary Outcome Measures

Local Tumor Control Rate
Kaplan-Meier estimates will be used.

Secondary Outcome Measures

Local Tumor Control
Time to local failure will be monitored continuously using Bayesian method.
Postoperative response to treatment assessed by MRI
Routine MRI of the spine with and without contrast will be obtained at each follow-up visit. These post-treatment scans will be analyzed and compared to baseline scans for assessment of treatment response and local control. Bilsky grading system will be used.
Adverse Events
To describe adverse side effects after treatment and descriptively correlate those effects with radiographic findings, pain control, and quality of life.
Overall Survival
Kaplan-Meier estimates will be used.
Changes in symptoms assessed by physical examination
The Physical Exam includes a general exam:(HEENT) Head, Eye, Ear, Nose and Throat evaluation, chest, heart, abdomen and extremities exam. Changes will be compared to baseline measurements. Negative changes will be evaluated by the neurosurgeon and radiation oncologist to determine if the change is related to a local failure or progression of systemic disease. Kaplan-Meier estimates will be used.
Changes in symptoms assessed by neurological examination
The neurological examination includes: mental status (tested through history taking), cranial nerves (observation of eyes, face, voice, and coordination during history taking and as patient moves about the exam room), motor system (visual inspection, tone, muscle strength and endurance, assigned score of 0-5 for each muscle, a score of 0 would mean no muscular contraction, and a score of 5 would mean movement against full resistance, normal strength), reflexes, sensory system (vibration in toes; pinprick in feet); coordination (truncal stability, fine finger movement, toe tapping, finger-nose-finger, heel-knee-shin), and station and gait (gait including arising from chair without hands, walking on toes, heels, and heel to toe). Kaplan-Meier estimates will be used.

Full Information

First Posted
July 2, 2021
Last Updated
September 13, 2023
Sponsor
Henry Ford Health System
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT05023772
Brief Title
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Official Title
A Clinical Trial Evaluating the Efficacy of Combining Laser Interstitial Thermal Ablation With and Without Spine Stereotactic Radiosurgery for Patients With Spine Metastases
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 2, 2021 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
September 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Henry Ford Health System
Collaborators
Medtronic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this research is to combine two complementary modes of treatment, spinal interstitial laser ablation and stereotactic spine radiosurgery (SSRS) for the treatment for spinal tumors near the spinal cord with an objective to improve tumor control, improve pain control, preserve function, and improve quality of life. We will also assess how effective these combined modes of treatment are in patients with spinal metastasis with an epidural component.
Detailed Description
Primary Objectives: Documenting rate of local control in patients who have received this combined treatment and Documenting safety of MRI compatible hardware for MRI based image guidance Determining the accuracy of the MRI-based image guidance Secondary Objectives: To determine local control at 1, 3, 6, 9, 18, and 24 months, and to compare to a historical control where patients received only SSRS at these time points and at 12 months. To document the extent of epidural tumor regression at 1, 3, 6, 9, 12, 18 and 24 months Calculate decrease in epidural tumor volume (by volumetric measurements using Brain Lab Elements software) Calculate increase in thecal sac patency (by volumetric measurements using Brain Lab Elements software and according to Bilsky method To determine overall survival at 6, 12, 18, and 24 months. To assess changes in muscle strength, location and severity of spinal-related pain, sensory function, ability to ambulate, and neurological grading at 1, 3, 6, 9, 12, 18, and 24 months compared with pretreatment baselines. To assess the effect of treatment on quality of life, measured at 1 month and every 3 months after with validated outcome measure tools To describe adverse side effects after treatment and to descriptively correlate those effects with radiographic findings, pain control, and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neoplasm Metastasis, Spinal Cord Diseases, Spinal Cord Compression, Spinal Cord Tumor, Spine Metastases
Keywords
Laser Ablation, Spinal Cord, Minimally Invasive Surgical Procedure, Stereotactic Radiosurgery, Pain Control, Metastasis, Epidural Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Open Label one arm. Unblinded.
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Treatment of Laser Interstitial Thermal Ablation Therapy and Stereotactic Radiosurgery
Arm Type
Experimental
Arm Description
Patients will undergo laser interstitial thermal ablation and CT guided stereotactic radiosurgery via intensity-modulated radiation therapy on different dates within a one to fourteen day window. The order of treatment is at the treating physicians discretion.
Intervention Type
Procedure
Intervention Name(s)
Stereotactic Laser Ablation
Other Intervention Name(s)
Thermal laser ablation therapy, Visualase laser ablation therapy
Intervention Description
MR Guided laser ablation therapy
Intervention Type
Radiation
Intervention Name(s)
Stereotactic Radiosurgery
Other Intervention Name(s)
CT guided stereotactic radiosurgery, Stereotactic external beam radiation therapy
Intervention Description
Precise delivery of radiation to spinal tumor
Intervention Type
Diagnostic Test
Intervention Name(s)
MRI guided laser ablation
Other Intervention Name(s)
Intraoperative MRI
Intervention Description
Surgery will take place in intraoperative suite to include operating room and MRI scanner
Primary Outcome Measure Information:
Title
Local Tumor Control Rate
Description
Kaplan-Meier estimates will be used.
Time Frame
up to 24 months
Secondary Outcome Measure Information:
Title
Local Tumor Control
Description
Time to local failure will be monitored continuously using Bayesian method.
Time Frame
1, 3, 6, 9, 12, 18, and 24 months
Title
Postoperative response to treatment assessed by MRI
Description
Routine MRI of the spine with and without contrast will be obtained at each follow-up visit. These post-treatment scans will be analyzed and compared to baseline scans for assessment of treatment response and local control. Bilsky grading system will be used.
Time Frame
1, 3, 6, 9, 12, 18, and 24 months
Title
Adverse Events
Description
To describe adverse side effects after treatment and descriptively correlate those effects with radiographic findings, pain control, and quality of life.
Time Frame
up to 24 months
Title
Overall Survival
Description
Kaplan-Meier estimates will be used.
Time Frame
6, 12, 18, and 24 months
Title
Changes in symptoms assessed by physical examination
Description
The Physical Exam includes a general exam:(HEENT) Head, Eye, Ear, Nose and Throat evaluation, chest, heart, abdomen and extremities exam. Changes will be compared to baseline measurements. Negative changes will be evaluated by the neurosurgeon and radiation oncologist to determine if the change is related to a local failure or progression of systemic disease. Kaplan-Meier estimates will be used.
Time Frame
1, 3, 6, 9, 12, 18, 24 months and annually thereafter
Title
Changes in symptoms assessed by neurological examination
Description
The neurological examination includes: mental status (tested through history taking), cranial nerves (observation of eyes, face, voice, and coordination during history taking and as patient moves about the exam room), motor system (visual inspection, tone, muscle strength and endurance, assigned score of 0-5 for each muscle, a score of 0 would mean no muscular contraction, and a score of 5 would mean movement against full resistance, normal strength), reflexes, sensory system (vibration in toes; pinprick in feet); coordination (truncal stability, fine finger movement, toe tapping, finger-nose-finger, heel-knee-shin), and station and gait (gait including arising from chair without hands, walking on toes, heels, and heel to toe). Kaplan-Meier estimates will be used.
Time Frame
1, 3, 6, 9, 12, 18, and 24 months
Other Pre-specified Outcome Measures:
Title
Measuring Quality of life (QOL) assessed by Spine Tumor Survey (MDASI-SP)
Description
We are measuring quality of life with the Spine Tumor Survey that will be assessed during each follow up Clinic visit. The patient survey will be assessed to measure postoperative response to treatment.
Time Frame
baseline and 1, 3, 6, 9, 12, 18, and 24 months
Title
Measuring Quality of life (QOL) assessed by Health Survey (SF-36)
Description
We are measuring quality of life with the Health Survey that will be assessed during each follow up Clinic visit. The participants are asked questions that measure eight health domains to assess physical and mental health. Physical health-related domains include: General health, Physical Functioning, Role Physical, and Body Pain. Mental health-related scales include Vitality, Social Functioning, Role Emotional, and Mental Health. A 3 and 5 point Likert scale is used in the survey. Two summary scores of the physical and mental health using weighted means of the eight domains. Descriptive statistics will be used to summarize pain relief and quality of life at each follow up visit, which will be the changes in scores from baseline to each assessment visit. Time to maximum pain relief will be the time from the day of thermal ablation until the lowest pain score for average pain after radiotherapy.
Time Frame
baseline and 1, 3, 6, 9, 12, 18, and 24 months
Title
Measuring Quality of life (QOL) assessed by Brief Pain Inventory Survey (BPI)
Description
We are measuring quality of life with the Brief Pain Inventory Survey that will be assessed during each follow up Clinic visit. The patient survey will be assessed to measure postoperative response to treatment. Participants are asked to assess the severity of pain and the impact of pain on daily functions. Severity of pain, including the pain location, worst pain in the last 24 hours, least pain in the last 24 hours, pain on average and pain right now. Range 0-10: a score of 0 would mean no pain and a score of 10 means the pain is as bad as you can imagine. Pain medications, amount of pain relief in the past 24 hours, and impact of pain on daily function, including general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life, and range 0-10.
Time Frame
baseline and 1, 3, 6, 9, 12, 18, and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years old. (The indication for this technique is controversial in skeletally immature patients.) Histologic diagnosis of solid malignant tumor (not one of the more radiosensitive histologic subtypes, see Exclusion Criteria), including but not limited to non-small cell lung cancer, breast, prostate, renal cell, melanoma, gastrointestinal, sarcoma, thyroid, head and neck primary, and unknown primary tumors. Quantification of the degree of epidural spinal cord compression as grade 1C, 2, or 3 by MRI, with and without contrast sequences. Axial T2 sequence is encouraged but not required. The vertebral body site to be treated must be located from T2 to L1 No more than 3 contiguous or dis-contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session or 3 sessions. Motor strength ≥4 out of 5 in extremity or extremities affected by the level of the spinal cord compression (see section 4 for grading method). ECOG performance status <2 or Karnofsky performance status (KPS) >50 Life expectancy >3 months. Inoperable disease because of patient refusal, neurosurgical evaluation, or any other medical reasons. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Prior conventional radiation to the same site is allowed as long as there is a greater than 3 months interval. Signed informed consent. Exclusion Criteria: Requires open spinal procedure or a percutaneous procedure without the use of image guidance. Primary tumors of radiosensitive histology (lymphoma, multiple myeloma, small cell carcinoma, germ cell tumors), as conventional radiation is likely to be effective in such cases. Unable to tolerate general anesthesia and prone position. Unable to undergo MRI scan of the spine. Inability to lie flat on a treatment table for >60 minutes. Pregnant. (Urine testing must be done no more than 10 days prior to surgery.) Prior conventional irradiation of the spine site and level to be treated with an interval shorter than 3 months. Frank cord compression or cord compression from bone components or configuration and acute neurological deficits (defined as motor strength <4/5 in extremity or extremities affected by the level of the spinal cord compression)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
RAMONA DAVIS
Phone
3132821753
Email
RDavis18@hfhs.org
First Name & Middle Initial & Last Name or Official Title & Degree
REHNUMA NEWAZ
Phone
3139164123
Email
RNewaz1@hfhs.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ian Lee, MD
Organizational Affiliation
Henry Ford Health Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
RAMONA DAVIS
Phone
313-282-1753
Email
RDavis18@hfhs.org
First Name & Middle Initial & Last Name & Degree
REHNUMA NEWAZ
Phone
3139164123
Email
RNewaz1@hfhs.org
First Name & Middle Initial & Last Name & Degree
IAN LEE, MD, FAANS
First Name & Middle Initial & Last Name & Degree
ADAM ROBIN, MD
First Name & Middle Initial & Last Name & Degree
MIRA SHAH, MD
First Name & Middle Initial & Last Name & Degree
SALIM SIDDIQUI, MD,PHD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases

We'll reach out to this number within 24 hrs